Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers

NCT02241720 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
5
Enrollment
OTHER
Sponsor class

Stopped Low Accrual

Conditions

Interventions

Sponsor

University of Utah